• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Bridging Study in China Completed for NASH Drug Candidate ASC40 prnasia
    July 20, 2020
    Ascletis Pharma Inc. (HKEX code: 1672) announces today that a single-dose, pharmacokinetic bridging study of non-alcoholic steatohepatitis (NASH) drug candidate ASC40 (TVB-2640) in 34 Chinese subjects has been completed and data indicates that key pharma

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service